Skip to main content
Fig. 1 | Renal Replacement Therapy

Fig. 1

From: Linagliptin inhibits lipopolysaccharide-stimulated interleukin-6 production, intranuclear p65 expression, and p38 mitogen-activated protein kinase phosphorylation in human umbilical vein endothelial cells

Fig. 1

Effects of linagliptin on lipopolysaccharide (LPS)-induced interleukin (IL)-6 production. Human umbilical vein endothelial cells (HUVECs) were treated with LPS and/or linagliptin. IL-6 levels in the supernatants were determined by ELISA after 5 h of treatment. **P < 0.01 vs. control; ## P < 0.01 vs. LPS 1 μg/mL. Lina linagliptin

Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us